Food allergy management is shifting from passive strategies — such as avoidance, carrying epinephrine and hope — to proactive ...

Desensitisation is possible. A family of treatments known as immunotherapies work by repeatedly exposing the body to tiny and gradually increasing amounts of allergen. For common allergens, such as ...

Amneal holds exclusive U.S. commercialization rights; BLA filing expected in Q4 2025 Poised to be among the first wave of biosimilars in the $3.9 billion U.S. omalizumab market and an important ...

EAACI: Dupixent demonstrated superiority over Xolair (omalizumab) in chronic rhinosinusitis with nasal polyps in patients with coexisting asthma in first-ever presented phase 4 head-to-head ...

EAACI: Dupixent demonstrated superiority over Xolair (omalizumab) in chronic rhinosinusitis with nasal polyps in patients with coexisting asthma in first-ever presented phase 4 head-to-head ...

The FDA has approved Omlyclo (omalizumab-igec), the first interchangeable biosimilar to Xolair (omalizumab).

OMLYCLO® (omalizumab-igec) is the first and only omalizumab biosimilar approved by the FDA Regulatory approval for interchangeability was supported by positive phase III data demonstrating comparable ...

A clinical trial has found that the medication omalizumab, marketed as Xolair, treated multi-food allergy more effectively than oral immunotherapy (OIT) in people with allergic reactions to very small ...

Omalizumab Treats Food Allergy More Effectively Than Immunotherapy Johns Hopkins Medicine study shows how a recently approved drug for food allergies compares to oral immunotherapy.